Page 3 - Pharma

No additional tariffs by US on Indian pharma, electronics so far: Govt

The government on Tuesday said no additional tariffs have been imposed on Indian exports to the US in sectors like pharmaceuticals, and electronics so far. In a written reply to the Lok Sabha, Minister of State for Commerce and Industry Jitin Prasada said reciprocal tariff at the rate of 25 per cent has been imposed on certain goods exported from India to the US, effective August 7. It is estimated that around 55 per cent of the total value of India's merchandise exports to the US is subjected to this reciprocal tariff, he said, adding that additional ad valorem rate of duty of 25 per cent with effect from August 27 has been imposed on certain goods exported from India. "No additional tariffs have been imposed on Indian exports to the US in sectors like pharmaceuticals, and electronics as yet," Prasada said. He also said the government is engaged with all stakeholders, including exporters and industry, for taking feedback of their assessment of the impact from the reciprocal tariff

Confident about Biocon's response to US tariffs: Kiran Mazumdar-Shaw

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon Chairperson

Pharma firms get one-month extension to submit declarations under UCPMP

The Department of Pharmaceuticals extends the deadline for pharma companies to file self-declarations, ensuring compliance with the Uniform Code for Pharmaceutical Marketing Practices (UCPMP)

Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025

806 applications approved so far under PLI schemes across 14 sectors

The government on Tuesday said as many as 806 applications have been approved under the Production Linked Incentive (PLI) schemes across 14 sectors as on date. The schemes for 14 key sectors including telecom, electronics, pharma, textiles and auto were announced with an outlay of Rs 1.97 lakh crore to enhance India's manufacturing capabilities and exports. It was announced in 2021. "As on date, 806 applications have been approved under PLI schemes across 14 sectors," Minister of State for Commerce and Industry Jitin Prasada said in a written reply to the Lok Sabha. He said that actual investment of Rs 1.76 lakh crore has been realised till March 2025 across 14 sectors, which has resulted in incremental production/sales of over Rs 16.5 lakh crore and employment generation of over 12 lakh (direct and indirect jobs). The pharmaceuticals sector has witnessed cumulative sales of Rs 2.66 lakh crore, which includes exports of Rs 1.70 lakh crore achieved in the first three years of the ..

Researchers map hair growth pathways for non-surgical hair restoration

The Esthetic Clinics and QR678 Research collaborate on groundbreaking research mapping hair growth pathways, potentially offering a non-surgical solution to hair restoration.

Wockhardt exits US generics biz, to focus on innovative portfolio

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

HC grants relief to Galderma against infringers using 'CETAPHIL' trademark

Bombay HC issues John Doe injunction allowing Galderma to take immediate action against counterfeit CETAPHIL products; seizures made in New Delhi and Mumbai

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE

Biocon Biologics gets EU nod for two drugs to treat bone diseases

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, expanding its portfolio in bone disease treatment

Pharma industry rebuts Siddaramaiah's claims on Covid vax, heart attacks

The chief minister said the government was probing if Covid vaccines -- which were "hastily approved" during the pandemic -- could be among the reasons behind these incidents

Apollo Hospitals to list digital health, pharmacy unit in 18-21 months

The hospital operator will retain a 15 per cent stake in the entity, which it is yet to be named, and will also have its nominee on the board of the new company

New data shows just how powerful the next weight-loss drugs may be

The drugs in development include a pill that a new trial suggests is about as effective as Ozempic

BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK

OneSource eyes weight-loss drug boost to order book

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses

Merck's potential cholesterol pill succeeds in late-stage studies

The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade

Dr Reddy's, Alvotech to co-develop biosimilar of cancer drug Keytruda

The partnership marks a strategic boost to Dr Reddy's oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry

Medical representatives barred from govt hospitals to stop pharma influence

The Centre's move seeks to curb the influence of pharmaceutical companies. Sharing of information must now happen through email or other digital platforms